SAB BIOTHERAPEUTICS, INC.
SABS evidence brief
What we can confirm
- BioSniper Score:
- 6.4 / 10
- Market Cap:
- $310.3M
- Lead Asset:
- sab-142 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for SABS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SABS
SAB Biotherapeutics (SABS) is a clinical-stage biopharmaceutical company developing gene therapies and a fully human anti-thymocyte immunoglobulin (SAB-142) for type 1 diabetes and other autoimmune diseases, with multiple programs in Phase 2 and Phase 3 trials.
Key risk: Cash runway risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$310.3M
Cash Runway
—
Lead Asset
sab-142 (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 13 clinical trials for SAB BIOTHERAPEUTICS, INC..
SAB Biotherapeutics (SABS) is a clinical-stage biopharmaceutical company developing gene therapies and a fully human anti-thymocyte immunoglobulin (SAB-142) for type 1 diabetes and other autoimmune diseases, with multiple programs in Phase 2 and Phase 3 trials.
- Cash & equivalents of $8.3M as of 2026-06-30 [sec]
- Net income of -$22.5M as of 2026-06-30 [sec]
- Shareholders' equity of $214.8M as of 2026-06-30 [sec]
- Lead candidate SAB-142 (human anti-thymocyte globulin) is in a Phase 2b trial for type 1 diabetes, with a Phase 3 start noted for 2026-01-14 [catalyst]
- Gene therapy programs include LX101 (RPE65) in Phase 3 for inherited retinal dystrophy and LX102 (nAMD) in Phase 3 for neovascular age-related macular degeneration [catalyst]
What works
- SAB-142 has advanced to a Phase 2b randomized, double-blind, placebo-controlled dose-finding study for type 1 diabetes, indicating structured clinical progression [catalyst]
- The company has received a Breakthrough T1D grant to support the SAB-142 study, reflecting external validation from a leading T1D research organization [news · published 2026-07-07]
- Multiple gene therapy programs (LX101, LX102) have reached Phase 3, suggesting a diversified pipeline beyond the lead autoimmune candidate [catalyst]
What to weigh
- The company reported a net loss of $22.5M for the period ending 2026-06-30, with cash of only $8.3M, indicating a high burn rate relative to cash on hand [sec]
- SAB-142 faces a competitive landscape including Tzield (teplizumab), insulin therapy, and other approved or withdrawn treatments for type 1 diabetes [pipeline]
- The company is still pre-revenue (clinical-stage), with no approved products generating sales, and its financial runway appears limited given the cash position [sec]
From the filings
Quoted directly from source documents.
SAB-142 Phase 2b trial start date
“Phase2_Start: A Phase 2b, Randomised, Double-Blind, Placebo-Controlled, Parallel-Arm Dose Finding Study Evaluating the Efficacy and Safety of SAB-142 for Delaying the Progression of Type 1 Diabetes (T1D) in Patients With Stage 3 New Onset of Type 1 Diabetes (NOT1D)”
Catalysts · November 25, 2025
Breakthrough T1D grant received
“SAB Biotherapeutics Receives Breakthrough T1D Grant To Advance SAB-142 Study In Newly Diagnosed Type 1 Diabetes”
News · July 7, 2026
Catalyst timeline
- 2025-11-25 · Phase 2b start for SAB-142 (type 1 diabetes) — A randomized, double-blind, placebo-controlled dose-finding study evaluating SAB-142 in Stage 3 new onset T1D patients.
- 2026-01-14 · Phase 3 start for LX102 (nAMD) — A Phase III, randomized, open-label, active-controlled study of subretinal LX102 in neovascular age-related macular degeneration.
- 2023-09-13 · Phase 3 start for LX101 (RPE65) — Efficacy and safety trial of rAAV-RPE65 gene therapy in biallelic RPE65 mutation-associated inherited retinal dystrophy.
Risks & what to watch (3)›
Key risks
- Cash runway risk — Cash of $8.3M as of 2026-06-30 against a net loss of $22.5M suggests limited runway without additional financing [sec]
- Competitive T1D landscape — SAB-142 competes with approved Tzield, insulin therapy, and other agents; some competitors have been withdrawn from the European market [pipeline]
- Pre-revenue stage — No approved products; all programs are clinical-stage, meaning no current product revenue to offset expenses [sec]
What to watch
- Phase 2b results for SAB-142 in type 1 diabetes, as the trial started in late 2025 [catalyst]
- Phase 3 data readouts for LX101 (RPE65) and LX102 (nAMD) gene therapy programs [catalyst]
- Financial updates and potential capital raises given the cash position of $8.3M as of 2026-06-30 [sec]
- Regulatory milestones or partnerships, such as the Breakthrough T1D grant announced in July 2026 [news · published 2026-07-07]
Sources: Catalysts · Competitor trials · News · Pipeline · Generated October 7, 2026 · How we verify sources →
Run SAB BIOTHERAPEUTICS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available SAB BIOTHERAPEUTICS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.11 · 0% dilution
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
76
Total value held
$266.2M
| Holder | Shares | Value |
|---|---|---|
| vivo capital, llc | 11,420,000 | $43.7M |
| caligan partners lp | 7,967,207 | $30.5M |
| perceptive advisors llc | 6,431,743 | $24.6M |
| commodore capital lp | 4,401,500 | $16.9M |
| ra capital management, l.p. | 4,401,500 | $16.9M |
| balyasny asset management l.p. | 3,760,439 | $14.4M |
| adage capital partners gp, l.l.c. | 3,405,553 | $13.0M |
| millennium management llc | 3,032,697 | $11.6M |
| woodline partners lp | 2,851,791 | $10.9M |
| vanguard capital management llc | 2,493,737 | $9.6M |
Showing top 10 of 76 institutional holders of SAB BIOTHERAPEUTICS, INC.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 3.6%
- Days to cover
- 5.7
- Shares short
- 2,418,434
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SABS short interestGovernance
Frequently asked questions
What is the AI investment thesis for SAB BIOTHERAPEUTICS, INC.?
SAB Biotherapeutics (SABS) is a clinical-stage biopharmaceutical company developing gene therapies and a fully human anti-thymocyte immunoglobulin (SAB-142) for type 1 diabetes and other autoimmune diseases, with multiple programs in Phase 2 and Phase 3 trials.
What is SAB BIOTHERAPEUTICS, INC.'s lead drug candidate?
SAB BIOTHERAPEUTICS, INC.'s most advanced tracked candidate is sab-142 (Phase 2) for Type 1 Diabetes.
Who is the CEO of SAB BIOTHERAPEUTICS, INC.?
Mr. Samuel J. Reich is the chief executive officer of SAB BIOTHERAPEUTICS, INC. (SABS).
Where is SAB BIOTHERAPEUTICS, INC. headquartered?
SAB BIOTHERAPEUTICS, INC. (SABS) is headquartered in Miami Beach, FL, United States.
What therapeutic areas does SAB BIOTHERAPEUTICS, INC. focus on?
SAB BIOTHERAPEUTICS, INC. develops therapies across Oncology, Gene Therapy, Immunology, Ophthalmology, Metabolic, Dermatology, Nephrology, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.